Rate My Professor Paul Chin

Dr. Paul Chin serves as a Senior Lecturer in the Department of Medicine at the University of Otago, Christchurch, within the Faculty of Medicine, and as a Senior Medical Officer (Clinical Pharmacologist) at Te Whatu Ora Health New Zealand – Waitaha Canterbury. He earned his MBChB from the University of Otago, completed a PhD, and holds Fellowship of the Royal Australasian College of Physicians (FRACP). His career includes prior appointments as Research Associate in the Department of Medicine (Christchurch) at the University of Otago from April 2012 to April 2014 and January 2015 onward. Chin received the Health Research Council of New Zealand Clinical Research Training Fellowship from 2012 to 2014. His research specializes in clinical pharmacology, with interests in therapeutic drug monitoring focusing on anticoagulants and antimicrobials, quality use of medicines, electronic prescribing, and clinical decision support.

Paul Chin has authored or co-authored over 59 publications, accumulating approximately 787 citations. Notable works include 'Pharmacogenetics of statin-induced myotoxicity' (Frontiers in Genetics, 2020), 'High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment' (Alimentary Pharmacology & Therapeutics, 2012), 'Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C' (Drugs in R&D, 2014), 'Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation' (Stroke, 2017), and 'A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time' (British Journal of Clinical Pharmacology, 2014). Recent publications encompass 'Indication-based prescribing and prescribing with indications, effects on documentation, medicines use, and clinical outcomes: A systematic review' (International Journal of Medical Informatics, 2026), 'Oral anticoagulation for adults with atrial fibrillation or venous thromboembolism' (Australian Prescriber, 2025), and 'Rivaroxaban plasma concentrations cannot be predicted from coagulation assays: Real-life experience from a tertiary hospital in New Zealand' (Therapeutic Drug Monitoring, 2025). His contributions advance pharmacokinetic monitoring, dosing optimization, pharmacogenetics, and prescribing safety, impacting clinical practice in hospital settings. Presentations include educational and clinical utility of electronic pre-prescribing at the AMEE Annual Conference (2025).